dairy calf-shutterstock_74603914.jpg Shutterstock

ImmuCell announces USDA approval of Dual-Force First Defense

Single-dose oral syringe provides guaranteed levels of Escherichia coli and coronavirus antibodies to prevent scours in newborn calves

ImmuCell Corp., a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, announced Dec. 11 that the U.S. Department of Agriculture has issued a product license for ImmuCell's Dual-Force First Defense.

Dual-Force in a single-dose oral syringe provides guaranteed levels of Escherichia coli and coronavirus antibodies to prevent scours in newborn calves, ImmuCell said. The gel tube delivery format is a preferred administration route for some, as an alternative to the company’s longstanding First Defense capsule.

“Our goal is to formulate our efficacious colostrum antibodies into a variety of formats so that our customers can choose the option that works best for their operations,” ImmuCell president and chief executive officer Michael F. Brigham said. “This regulatory validation should help us compete more effectively in the market and grow sales.”

“Quicker and easier administration is what we were aiming for when we made the decision to formulate our E. coli and coronavirus antibodies into a gel tube,” added Bobbi Jo Brockmann, vice president of sales and marketing. “This product offers a non-digestible blue dye that serves as a marker, turning the calf’s first stool after administration neon blue-green to help detect and prevent protocol drift.”

ImmuCell's purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle.

 

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish